The Centre for Drug Research and Development (CDRD) is a Canadian non-profit organization that serves as an integrated national drug development and commercialization center. CDRD’s mandate is to de-risk discoveries stemming from publicly funded health research and transform them into viable investment opportunities for the private sector.

**Mission**

The mission of CDRD is to be a global leader in translating academic discoveries into new medicines; to bridge the commercialization gap between drug discovery and private investment by creating partnerships between academia, industry, and government that mobilize scientific excellence and enable a robust biopharmaceutical sector; and to provide the next generation of uniquely trained highly qualified personnel to drive the development of the medicines of tomorrow.

**Structure & Governance**
CDRD is governed by an independent board of directors comprised of a cross-section of public- and private-sector stakeholder groups.

In order to ensure all projects are initiated and subsequently managed with the highest level of objectivity and scientific and commercial excellence, CDRD relies on the following committees to determine which projects are selected for development and funding within CDRD, and to provide oversight on the progress of all CDRD projects.

Project Development Committee (PDC) is responsible for the peer review to determine which projects are undertaken within CDRD, and for assisting with the design and approval of Project Plans. It is composed of individuals with broad and considerable drug discovery expertise, including CDRD division chairs, CEO, scientific director, and director of scientific operations, as well as additional faculty members at affiliated institutions who serve as strategic advisors. Independent academic experts, including clinicians, are also called upon to provide additional input on specific proposals when needed.

Innovation Fund Review Panels review, assess, and recommend projects for funding by each of CDRD’s three Innovation Funds, and provide valuable input into Project Plans. These panels are comprised of CDRD division chairs, independent members, and members of the respective industry partner. Panel membership is selected jointly by CDRD and the partner.

Financing

CDRD has multiple funding partners including federal government organizations, provincial government organizations, and industry and foundations.

Since becoming fully operational in 2008, CDRD has already achieved a number of key milestones and outcomes, making a significant impact on Canada’s drug development environment.

Highlights of outcomes to date:

- 800 potential projects/technologies reviewed
- 125 full projects undertaken
- 174 individual project iterations
44 projects advanced towards commercialization and/or commercialized (35 ongoing)
6 technologies out-licensed to the private sector or under current development/management of CVI
4 spin-off companies launched
33 new patent families supported with CDRD data
23 collaborations on scientific publications
$75.2 million in grant funding facilitated for principal investigators and their CDRD-related projects
Over $40 million in international pharmaceutical sector investment attracted
$220 million in incremental commercially focused health research being conducted as result of CDRD
110 post-doctoral fellows, co-op students, and interns through the CDRD Training Program
Over 98 drug development and commercialization workshops and seminars offered

See more at http://www.cdrd.ca/about-us/key-achievements/#sthash.mtO6s6FR.dpuf

Points of Contact

For Investigators:
Dr. Sam White
Associate Director, Project Search and Evaluation
swhite@cdrd.ca
604.827.1215

Sponsors & Partners

Pfizer
GlaxoSmithKline
Johnson & Johnson
Provincial Government of British Columbia
Provincial Government of Alberta
Genome British Columbia
Networks of Centers of Excellence of Canada
Canada Foundation for Innovation
Western Economic Diversification Canada
Canadian Institutes of Health Research
Michael Smith Foundation for Health Research
Roche
Angiotech
QLT Inc.
Merck
Cystic Fibrosis Canada

Updated: 04/22/2016